The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus.
Alexander T, Sarfert R, Klotsche J, Kühl AA, Rubbert-Roth A, Lorenz HM, Rech J, Hoyer BF, Cheng Q, Waka A, Taddeo A, Wiesener M, Schett G, Burmester GR, Radbruch A, Hiepe F, Voll RE.
Alexander T, et al. Among authors: hoyer bf.
Ann Rheum Dis. 2015 Jul;74(7):1474-8. doi: 10.1136/annrheumdis-2014-206016. Epub 2015 Feb 20.
Ann Rheum Dis. 2015.
PMID: 25710470
Free PMC article.
Clinical Trial.